Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
23.81%
Operating Margin
10.84%
Net Margin
5.46%
Efficiency Metrics
Revenue per Expense Ratio
1.12
R&D as % of Revenue
1.29%
Earnings Quality
EBITDA Margin
17.28%
Income Tax Rate
36.93%
EPS
1.7500000000
Balance Sheet Analysis
Current Ratio
1.47
Cash Ratio
0.09
Working Capital
$205.80M
Debt to Equity
1.94
Debt to Assets
50.57%
Equity Ratio
26.10%
Cash Flow Analysis
Operating Cash Flow Ratio
18.26%
Free Cash Flow Ratio
9.14%
CapEx to Revenue
9.12%
Dividends Paid
$4.90M
Stock Buybacks
$65.60M
Total Shareholder Returns
$70.50M
Cash Position Change
-36.59%
Key Takeaways (2023 FY)
Revenue declined by 6.7457777340096%, indicating potential market challenges
Increased dividend payments by 1.17%
Increased R&D investment by 12.90%
Detailed Growth Metrics
Core Performance
Revenue
-6.75%
Net Income
-2.54%
EPS
0.57%
Operating Income
4.16%
Operational Efficiency
R&D Expenses
12.90%
SG&A Expenses
-2.29%
Operating Cash Flow
327.04%
Free Cash Flow
214.03%
Balance Sheet Health
Assets
-2.93%
Debt
1.30%
Book Value per Share
7.52%
Inventory
3.31%
Shareholder Returns
Dividends per Share
1.17%
Shares Outstanding
-3.13%
Long Term Trends
3Y Revenue/Share
70.71%
5Y Revenue/Share
21.17%
3Y Dividend/Share
-58.33%
5Y Dividend/Share
-89.62%